ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Lyell Immunopharma
This role supports the Manufacturing, Science and Technology (MSAT) organization at Lyell, contributing to the operation of a clinical-stage cell therapy manufacturing site. The position helps enable delivery of next-generation CAR T-cell therapies by supporting reliable GMP manufacturing and fostering cross-functional collaboration. The role is based on-site and operates within a fast-paced, shift-based environment.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2018
Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lyell Immunopharma.
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation
5 days ago
